Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Poor insight is common in schizophrenia, predictive of non-compliance, and an impediment to effective patient management. We hypothesized that long-acting risperidone would be associated with enhanced insight, contributing to improved quality of life measures. In an international, open-label 50-week study, stable patients received long-acting risperidone every 2 weeks. Assessments included the Positive and Negative Syndrome Scale [PANSS; item G12 rated 'impaired insight and judgment' from 1 (no impairment) to 7 (severe impairment)]; Clinical Global Impressions-Severity (CGI-S); and the Medical Outcomes Study Short-form 36-item Health Survey (SF-36) (patient-rated quality of life). Correlation and regression post-hoc analyses examined associations between insight and other measures. At baseline, 314 (51.1%; N=614) patients had impaired insight (G12=3-7) and 83 (26.4%) achieved normal or near normal ratings at endpoint (G12=1-2). Symptom severity corresponded with insight: baseline mean+/-SD PANSS total scores were 56.0+/-14.4 in patients without impaired insight (G12=1-2); 73.4+/-15.7 with mild-moderate impairment (G12=3-4); and 86.0+/-17.4 with severe impairment (G12=5-7). These scores improved significantly in each group at endpoint (P<0.001). Improved insight ratings correlated with improvements in CGI-S (r=0.37); PANSS disorganized thought (r=0.46); negative symptoms (r=0.32); and anxiety/depression (r=0.24; P<0.001 all comparisons), but not quality of life ratings. The change in insight did not contribute significantly to the variance in SF-36 scores; however, changes in negative symptoms, anxiety/depression and CGI-S scores did contribute significantly. Long-acting risperidone was associated with improvements in insight, symptom domains, clinical status and quality of life measures. Associations were noted between patient-rated quality of life and specific symptom domains, but not insight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 1×
“Moreover, individual studies, as well as a meta-analysis, suggest that poor insight is associated with poor compliance or that higher levels of insight correlate with better compliance (Amador et al., 1991; Lacro et al., 2002).”
ResultCsernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
Insight in schizophrenia: a meta-analysis
Mintz, A. R., Dobson, K. S., & Romney, D. M. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00316-x · Cited by 563 · cited 4×
“By contrast to other reports (Amador et al., 1994; Kemp and Lambert, 1995; Moore et al., 1999; Smith et al., 2000; Mintz et al., 2003), our data suggest a All data expressed as mean ± SD unless otherwise noted.”
BackgroundResultInfluential
Cited by
Lincoln, T. M., Lullmann, E., & Rief, W. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm002 · Cited by 486
LINCOLN, T., WILHELM, K., & NESTORIUC, Y. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.022 · Cited by 317
Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., & Lieberman, J. A. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn067 · Cited by 258
Belvederi Murri, M., Respino, M., Innamorati, M., Cervetti, A., Calcagno, P., Pompili, M., Lamis, D. A., Ghio, L., & Amore, M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.003 · Cited by 142
Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
Stevens, G. L., Dawson, G., & Zummo, J. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12278 · Cited by 109
Metadata
- Authors
- Gharabawi, G. M., Lasser, R. A., Bossie, C. A., Zhu, Y., & Amador, X.
- Venue
- International Clinical Psychopharmacology
- Published
- 2006-07
- Volume
- 21
- Issue
- 4
- Pages
- 233-240
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1971670257
- Cited by
- 75
- References
- 4
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. https://app.cochat.ai/papers/10.1097/00004850-200607000-00006
- The paper
- Gharabawi, G. M., Lasser, R. A., Bossie, C. A., Zhu, Y., & Amador, X. (2006). Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200607000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.